Safety and efficacy study of nasopharyngeal cancer stem cell vaccine
| Autor: | Jibing Chen, Jongyuan Xu, Yuanying Yuan, Xiaoling Cai, Mao Lin, Lizhi Niu, Kecheng Xu, Qiao Li, Shupeng Liu |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty medicine.medical_treatment Immunology Cancer Vaccines Peripheral blood mononuclear cell Immunophenotyping Immune system Cancer stem cell Internal medicine Injection site reaction medicine Humans Immunology and Allergy Aged Neoplasm Staging Cancer prevention business.industry Vaccination Nasopharyngeal Neoplasms Immunotherapy Middle Aged medicine.disease Combined Modality Therapy Lymphocyte Subsets Clinical trial Neoplastic Stem Cells Female Stem cell business Biomarkers |
| Zdroj: | Immunology Letters. 165:26-31 |
| ISSN: | 0165-2478 |
| DOI: | 10.1016/j.imlet.2015.03.005 |
| Popis: | In this trial, nasopharyngeal cancer stem cells (CSCs) were separated and cultured to produce a vaccine; its safety and efficacy were prospectively evaluated in low-, medium-, and high-dose groups. Between April and September 2014, we enrolled 90 patients who met the enrolment criteria, and assigned them to three groups (n=30). Throughout the trial, injection site reaction was the most common reaction (81%), and fever was least common (31%); however, there was no difference among the three groups. When the immune responses pre- and post-vaccination were compared, we found that the CSC-specific and -nonspecific response in the medium- and high-dose groups were both significantly enhanced. This study is the first clinical trial of a nasopharyngeal CSC vaccine and preliminarily proves its safety and efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect